Dr. Bill Hunter is responsible for the assembly of the Company’s management team, the development of corporate strategic initiatives and participation in both business development and corporate finance activities.
Bill brings 30 years of experience in healthcare as a former practicing physician, serial medtech entrepreneur and chief executive. He most recently was CEO of Correvio (CORV:NASDAQ) where he oversaw the development of its own direct sales force in Europe, acquiring of a company with a complementary product (AGGRASTAT), assembling of an international distribution network, in-licensing three additional products and increasing valuation by over five-fold. Prior to that, he was Founder/CEO of Angiotech (ANPI:NASDAQ), a world leader in the emerging field of drug-loaded medical devices and implants and achieved a market capitalization of greater than $2 billion.
He is an innovator and inventor with over 200 patents and patent applications, including the discovery and development of Persona IQ, the TAXUS® Drug-Eluting Coronary Stent, the Ranger® drug eluting balloon, the Zilver PTX Peripheral Drug-Eluting Stent and the Quill barbed wound closure device. He has overseen the development of products used in over 50 million patients, generating revenues of over $25 billion.
Bill holds a Doctorate of Medicine from University of British Columbia, a Master of Science from University of British Columbia and a Bachelor of Science from McGill University.
